August 06, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : ***Outcome of Board Meeting-August 06, 2026***

Stock Code : ***BSE – 539787, NSE – HCG***

Reference : ***Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")***

Further to our intimation dated July 27, 2026, and pursuant to Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company at its meeting held on August 06, 2026, has, *inter alia*, considered and approved the following agenda:

i. Unaudited Financial Results of the Company (Standalone and Consolidated), for the quarter ended June 30, 2026.
ii. Re-appointment of M/s. Rao Murthy & Associates (Firm Registration No. 000065), Cost Accountants, Bengaluru as the Cost Auditor of the Company for the financial year 2026-27.
iii. Further investment of up to INR 16 Crore in HCG Rajkot Hospitals LLP, wholly owned subsidiary of the Company.

In this regard, please find enclosed herewith the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The financial results are also being made available on the website of the Company and can be accessed at: https://www.hcgoncology.com/

The meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 06.50 p.m.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,
For **HealthCare Global Enterprises Limited**
SUNU MANUEL ABEY
Digitally signed by SUNU MANUEL ABEY
Date: 2026.08.06 18:52:11 +05'30'
Sunu Manuel
Company Secretary & Compliance Officer
Encl: a/a.

B S R & Co. LLP
Chartered Accountants

Embassy Golf Links Business Park
Pebble Beach, B Block, 3rd Floor
No. 13/2, off Intermediate Ring Road
Bengaluru - 560 071, India
Telephone: +91 80 4682 3000
Fax: +91 80 4682 3999

Limited Review Report on unaudited standalone financial results of HealthCare Global Enterprises Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of HealthCare Global Enterprises Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

Registered Office:
14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Vikash Gupta

Vikash Gupta
Partner
Membership No.: 064597
UDIN:26064597HLENIJ7833

Bangalore
06 August 2026

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended 30 June 2026	Preceding quarter ended 31 March 2026	Corresponding quarter ended 30 June 2025	Previous year ended 31 March 2026
		Unaudited	(Refer note 2)	Unaudited	Audited
1	**Income**				
	(a) Revenue from operations	37,525	34,847	32,593	135,937
	(b) Income from government grant	141	174	116	593
	(c) Other income	956	1,492	794	2,967
	Total income	**38,622**	**36,513**	**33,503**	**139,497**
2	**Expenses**				
	(a) Purchases of medical and non-medical items	9,561	9,513	8,424	35,864
	(b) Changes in inventories	(360)	(308)	(361)	(548)
	(c) Employee benefits expense	5,967	5,078	5,641	21,192
	(d) Finance costs	2,173	2,019	2,430	8,646
	(e) Depreciation and amortisation expense	3,957	3,130	2,825	11,980
	(f) Medical consultancy charges	7,734	6,675	6,428	26,343
	(g) Other expenses	8,842	6,549	7,592	29,520
	Total expenses	**37,874**	**32,656**	**32,979**	**132,997**
3	**Profit before exceptional items and tax (1-2)**	**748**	**3,857**	**524**	**6,500**
4	**Exceptional items (refer note 3)**	-	(4,752)	-	(5,538)
5	**Profit /(loss) before tax (3+4)**	**748**	**(895)**	**524**	**962**
6	**Tax expense**				
	- Current tax (refer note 7)	362	(820)	334	404
	- Deferred tax	(172)	(228)	(155)	(900)
	Total tax expense	**190**	**(1,048)**	**179**	**(496)**
7	**Profit for the period /year (5-6)**	**558**	**153**	**345**	**1,458**
8	**Other comprehensive income / (loss)**				
	Items that will not be reclassified subsequently to profit or loss				
	- Remeasurements of the defined benefit plans	-	(14)	-	11
	- Income tax effect on above	-	3	-	(3)
	Other comprehensive income/ (loss) for the period / year, net of tax	**-**	**(11)**	**-**	**8**
9	**Total comprehensive income for the period / year (7+8)**	**558**	**142**	**345**	**1,466**
10	Paid-up equity share capital (Face value of Rs. 10 each)	14,930	14,930	13,942	14,930
11	Reserves, i.e., 'Other equity'				145,548
12	**Earnings/(loss) per equity share (face value of Rs. 10 each)**	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic (Rs.) (refer note 4)	0.37	0.11	0.25	1.03
	(b) Diluted (Rs.) (refer note 4)	0.37	0.11	0.24	1.03
	See accompanying notes to the Standalone Financial Results				

MM

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

Notes:

1 This statement of standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter ended 30 June 2026 has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 06 August 2026. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditor of the Company. The report of the statutory auditor is unqualified.

2 The figures for preceeding quarter ended 31 March 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the end of the third quarter of the previous financial year, which were subject to limited review by the statutory auditors of the Company.

3 **Exceptional items:**

(i) During the quarter and previous year ended 31 March 2026, the management committed to a plan to divest the Company's entire equity interest in BACC Healthcare Private Limited ("BACC"), a wholly owned subsidiary engaged in the management of infertility treatment hospitals. Pursuant to the investor outreach process, non-binding offers were received from potential investors. Accordingly, the Company's investment in BACC, which was previously carried at cost less provision for diminution in value of investment, was reclassified as an "Investments classified as held for sale". Consequently, the investment was measured at the lower of its carrying amount and fair value less costs to sell. Accordingly, an impairment loss of Rs. 3,752 lakhs was recognised as an exceptional item for the preceding quarter and previous year ended 31 March 2026 based on the fair value of the consideration receivable, net of related expenses.

During the current quarter, based on the recommendation of the Audit Committee, and pursuant to the approval of the Board of Directors at its meeting held on 19 May 2026, the Company has completed the divestment of its entire equity interest in BACC to Inviga Healthcare Fund I and its nominee, a related party, for a consideration of Rs. 3,764 lakhs on 29 June 2026. Of the said consideration, Rs. 2,823 lakhs has been received upfront and the balance Rs. 941 lakhs is receivable within 18 months from the date of sale. Consequent to completion of the transaction, BACC has ceased to be a subsidiary of the Company with effect from 30 June 2026.

(ii) During the quarter and previous year ended 31 March 2026, the recoverable amount of the Company's investment in HCG Kolkata Cancer Care LLP (formerly HCG EKO Oncology LLP), a wholly-owned subsidiary, was estimated to be lower than its carrying value, resulting in an impairment of Rs. 3,000 lakhs. As at 31 March 2026, the Company carried total investment of Rs 13,157 lakhs in HCG Kolkata Cancer Care LLP, against which the cumulative provision for impairment is Rs 6,120 lakhs During the same period, based on a sustained improvement in operating performance of HCG Manavata Oncology LLP, a subsidiary, the conditions that had led to an impairment in earlier years no longer exist and accordingly an impairment reversal of Rs 2,000 lakhs was recognised. As at 31 March 2026, the Company's aggregate investment in HCG Manavata Oncology LLP amounts to Rs. 5,715 lakhs

(iii) During the previous year ended 31 March 2026, pursuant to the notification of new Labour Codes by the Government of India on 21 November 2025 resulting in change in wage definition, the incremental impact on the gratuity of Rs 640 lakhs and compensated absences of Rs 146 lakhs was recognised as an exceptional item, consistent with the guidance provided by the Institute of Chartered Accountants of India.

4 During the previous year ended 31 March 2026, the Company had completed a rights issue of 8,294,566 fully paid up equity shares of face value Rs. 10 each at an issue price of Rs. 512 per equity share (including a securities premium of Rs 502 per equity share), aggregating to Rs 42,468 lakhs. Share issue expenses amounting to Rs. 483 lakhs was adjusted against the securities premium reserve as per the applicable Ind AS and regulations. During the current quarter, the entire issue proceeds have been fully utilised for the objects specified in the Letter of Offer

Earnings per share for the correspoding quarter ended 30 June 2025 has been retrospectively adjusted for the bonus element in respect of Rights issue.

5 Pursuant to the Share Purchase Agreement (the "Agreement") dated 28 June 2024 with Vizag Hospital And Cancer Research Centre Private Limited ("VHCRPL") and its shareholders, the Company had acquired 51% equity shares of VHCRPL on 1 October 2024 for a consideration of Rs. 20,632 lakhs and acquired control of VHCRPL with effect from 2 October 2024. Further, as per the terms of the Agreement, the Company had committed to acquire an additional 34% of the equity share capital of VHCRPL for a consideration of Rs. 15,400 lakhs (approx.) which was payable within 18 months from the date of first closing (i.e., 1 October 2024). The consideration for the balance 15% of the equity share capital will be determined as per the terms of the shareholders' agreement.

During the current quarter, on 13 April 2026, the Company completed the acquisition of the said additional 34% equity share capital of VHCRPL for an aggregate purchase consideration of Rs. 15,450 lakhs.

6 During the previous year ended 31 March 2026, the Board of Directors had approved the introduction and adoption of the HCG Employee Stock Option Scheme 2026 ("HCG ESOS 2026"), under which the maximum number of options that can be granted is 74,21,455. Subsequent to the current quarter, the shareholders of the Company have, by way of special resolutions passed through postal ballot on 8 July 2026, approved (i) the introduction and adoption of HCG ESOS 2026 to eligible employees and (ii) the grant of up to 18,55,364 options (representing 1.24% of the diluted equity share capital) to Dr. Manish Mattoo, Executive Director and Chief Executive Officer of the Company, in one or more tranches. The implementation of HCG ESOS 2026 remains subject to receipt of approvals as may be required under applicable laws.

7 The income tax expenses for the preceding quarter and previous year ended 31 March 2026, is net of Rs 1,820 lakhs relating to reversal of income taxes with respect to earlier years.

8 The Company has a single operating segment viz 'setting up and managing hospitals and medical diagnostic services'.

For and on behalf of the Board of Directors

Manish

Dr. Manish Mattoo
Executive Director And Chief Executive Officer

Bangalore, 06 August 2026

HEALTHCARE GLOBAL ENTERPRISES LTD. Bengaluru

MG

B S R & Co. LLP
Chartered Accountants

Embassy Golf Links Business Park
Pebble Beach, B Block, 3rd Floor
No. 13/2, off Intermediate Ring Road
Bengaluru - 560 071, India
Telephone: +91 80 4682 3000
Fax: +91 80 4682 3999

Limited Review Report on unaudited consolidated financial results of HealthCare Global Enterprises Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of HealthCare Global Enterprises Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its joint venture for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I of this limited review report.

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

VY.

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

Registered Office:
14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

7. We did not review the interim financial information of 11 Subsidiaries and 6 step down subsidiaries included in the Statement, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs. 14,990 Lakhs, total net profit after tax (before consolidation adjustments) of Rs. 520 Lakhs and total comprehensive income (before consolidation adjustments) of Rs. 569 Lakhs, for the quarter ended 30 June 2026, as considered in the Statement. The Statement also include the Group's share of net profit after tax of Rs. 93 Lakhs and total comprehensive income of Rs. 93 Lakhs, for the quarter ended 30 June 2026 as considered in the Statement, in respect of a joint venture, whose interim financial information has not been reviewed by us. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and a joint venture, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Vikash Gupta

Vikash Gupta

Partner

Membership No.: 064597

UDIN:26064597IODPPV3849

Bangalore

06 August 2026

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary (Till 29 June 2026)	India
2	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HCG Oncology Hospitals LLP (formerly known as Apex HCG Oncology Hospitals LLP)	Subsidiary	India
5	HCG Manavata Oncology LLP	Subsidiary	India
6	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
7	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
8	HCG NCHRI Oncology LLP	Subsidiary	India
9	Nagpur Cancer Hospital & Research Institute Private Limited	Subsidiary	India
10	HCG Kolkata Cancer Care LLP (formerly known as HCG EKO Oncology LLP)	Subsidiary	India
11	HCG Rajkot Hospitals LLP (formerly known as HCG Sun Hospitals LLP)	Subsidiary	India

Sr. No	Name of component	Relationship	Country of incorporation
12	Niruja Product Development & Healthcare Research Private Limited	Subsidiary	India
13	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
14	Suchirayu Health Care Solutions Limited	Subsidiary	India
15	HCG (Mauritius) Pvt. Ltd.	Subsidiary	Mauritius
16	Vizag Hospital & Cancer Research Centre Private Limited	Subsidiary	India
17	HealthCare Global (Africa) Private Limited	Step-down subsidiary	Mauritius
18	Healthcare Global (Uganda) Private Limited	Step-down subsidiary	Uganda
19	Healthcare Global (Kenya) Private Limited	Step-down subsidiary	Kenya
20	Cancer Care Kenya Limited	Step-down subsidiary	Kenya
21	Vizag Hospital & Cancer Research Centre (Jharsuguda) Private Limited	Step-down subsidiary	India
22	Vizag Hospital & Cancer Research Centre (Odisha) Private Limited	Step-down subsidiary	India
23	Advanced Molecular Imaging Limited	Joint Venture	Kenya

VY.

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended 30 June 2026	Preceding quarter ended 31 March 2026	Corresponding quarter ended 30 June 2025	Previous year ended 31 March 2026
		Unaudited	(Refer note 2)	Unaudited	Audited
1	**Income**				
	(a) Revenue from operations	69,339	65,029	61,180	253,843
	(b) Income from government grant	171	204	136	698
	(c) Other income (refer notes 3 and 5 (b))	1,213	1,307	683	2,499
	Total income	**70,723**	**66,540**	**61,999**	**257,040**
2	**Expenses**				
	(a) Purchases of medical and non-medical items	18,684	18,070	16,633	70,168
	(b) Changes in inventories	(804)	(399)	(446)	(938)
	(c) Employee benefits expense	10,452	9,247	9,777	37,860
	(d) Finance costs	3,987	4,270	4,547	17,657
	(e) Depreciation and amortisation expense	7,042	6,281	5,791	24,417
	(f) Medical consultancy charges	15,747	14,033	13,302	54,907
	(g) Other expenses	13,205	11,774	11,271	45,965
	Total expenses	**68,313**	**63,276**	**60,875**	**250,036**
3	**Profit before share of profit/(loss) of joint venture, exceptional items and tax (1-2)**	**2,410**	**3,264**	**1,124**	**7,004**
4	Share of profit / (loss) of joint venture	93	52	68	146
5	**Profit before exceptional items and tax (3+4)**	**2,503**	**3,316**	**1,192**	**7,150**
6	**Exceptional item (refer note 3)**	-	(3,191)	-	(4,458)
7	**Profit /(loss) before tax (5+6)**	**2,503**	**125**	**1,192**	**2,692**
8	**Tax expense**				
	- Current tax (refer note 6)	870	(161)	891	1,976
	- Deferred tax (refer note 6)	(13)	(118)	(297)	(1,562)
	Total tax expense/(credit)	**857**	**(279)**	**594**	**414**
9	**Profit / (loss) for the period / year (7-8)**	**1,646**	**404**	**598**	**2,278**
10	**Other comprehensive income/ (loss)**				
	(i) Items that will not be reclassified subsequently to profit or loss				
	- Remeasurements of the defined benefit plans	-	12	-	97
	- Income tax effect on above	-	(1)	-	(24)
	(ii) Items that will be reclassified to profit or loss				
	- Exchange differences on translation of financial statements of foreign operations	49	154	25	382
	Other comprehensive income for the period / year, net of tax	**49**	**165**	**25**	**455**
11	**Total comprehensive income / (loss) for the period / year (9+10)**	**1,695**	**569**	**623**	**2,733**
	Profit for the period / year attributable to:				
	Owners of the Company	1,377	217	475	1,376
	Non-controlling interests	269	187	123	902
	Other comprehensive income / (loss) for the period / year attributable to				
	Owners of the Company	47	209	17	455
	Non-controlling interests	2	(44)	8	-
	Total comprehensive income for the period / year attributable to				
	Owners of the Company	1,424	426	492	1,831
	Non-controlling interests	271	143	131	902
12	Paid-up equity share capital (Face value of Rs. 10 each)	14,930	14,930	13,942	14,930
13	Reserves, i.e., 'Other equity'				118,267
14	**Earnings / (loss) per equity share (face value of Rs. 10 each)**	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic (Rs.) (refer note 4)	0.92	0.15	0.34	0.97
	(b) Diluted (Rs.) (refer note 4)	0.92	0.15	0.33	0.96
	See accompanying notes to the Consolidated Financial Results				

MM

Ald

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

Notes to conoslidated financial results:

1 This statement of consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), and its subsidaries (collectively referred to as "the Group") and its joint venture for the quarter ended 30 June 2026 has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 06 August 2026. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditor of the Company. The report of the statutory auditor is unqualified.

2 The figures for preceeding quarter ended 31 March 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the end of the third quarter of the previous financial year, which were subject to limited review by the statutory auditors of the Company.

3 **Exceptional items:**

(i) During the quarter and pevious year ended 31 March 2026, the management committed to a plan to divest the Company's entire equity interest in BACC Healthcare Private Limited ("BACC"), a wholly owned subsidiary engaged in the management of infertility treatment hospitals. Accordingly, the assets and liabilities of BACC were classified as a disposal group held for sale as at 31 March 2026. Along with the classification as held for sale, the carrying amount of goodwill allocated to the cash-generating unit (i.e., BACC) was assessed for impairment in accordance with Ind AS 36 and an impairment loss of Rs. 3,191 lakhs was recognised as an exceptional item for the preceding quarter and previous year ended 31 March 2026 based on the fair value of the consideration receivable, net of related expenses.

During the current quarter, based on the recommendation of the Audit Committee, and pursuant to the approval of the Board of Directors at its meeting held on 19 May 2026, the Company has completed the divestment of its entire equity interest in BACC to Inviga Healthcare Fund I and its nominee, a related party, for a consideration of Rs. 3,764 lakhs on 29 June 2026 and has recognised resulting gain of Rs. 296 lakhs in Other income. Of the said consideration, Rs. 2,823 lakhs has been received upfront and the balance Rs. 941 lakhs is receivable within 18 months from the date of sale. Consequent to completion of the transaction, BACC has ceased to be a subsidiary of the Company with effect from 30 June 2026.

(ii) During the quarter and previous year ended 31 March 2026, pursuant to the notification of new Labour Codes by the Government of India on 21 November 2025 resulting in change in wage definition, the incremental impact on the employee benefit obligations aggregating Rs. 1267 lakhs was recognised as an exceptional item, consistent with the guidance provided by the Institute of Chartered Accountants of India.

4 During the previous year ended 31 March 2026, the Company had completed a rights issue of 8,294,566 fully paid up equity shares of face value Rs. 10 each at an issue price of Rs. 512 per equity share (including a securities premium of Rs. 502 per equity share), aggregating to Rs. 42,468 lakhs. Share issue expenses amounting to Rs. 483 lakhs was adjusted against the securities premium reserve as per the applicable Ind AS and regulations. During the current quarter, the entire issue proceeds have been fully utilised for the objects specified in the Letter of Offer.

Earnings per share for the correspoding quarter ended 30 June 2025 has been retrospectively adjusted for the bonus element in respect of Rights issue.

5 (a) Pursuant to the Share Purchase Agreement (the "Agreement") dated 28 June 2024 with Vizag Hospital And Cancer Research Centre Private Limited ("VHCRPL") and its shareholders, the Company had acquired 51% equity shares of VHCRPL on 1 October 2024 for a consideration of Rs. 20,632 lakhs and acquired control of VHCRPL with effect from 2 October 2024. Further, as per the terms of the Agreement, the Company had committed to acquire an additional 34% of the equity share capital of VHCRPL for a consideration of Rs. 15,400 lakhs (approx.) which was payable within 18 months from the date of first closing (i.e., 1 October 2024). The consideration for the balance 15% of the equity share capital will be determined as per the terms of the shareholders' agreement.

During the current quarter, on 13 April 2026, the Company completed the acquisition of the said additional 34% equity share capital of VHCRPL for an aggregate purchase consideration of Rs. 15,450 lakhs.

(b) During the preceding quarter ended 31 March 2026, the Group had recognised a gain of Rs. 700 lakhs in respect of trade receivables acquired through the business combination referred to above (accounted for under Ind AS 103 "Business Combinations"), on account of changes in the fair value (recoverability) of these receivables.

MM

Ac2

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489
Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

6 (a) The income tax expenses for the preceding quarter and previous year ended 31 March 2026, is net of Rs 1,820 lakhs relating to reversal of income taxes with respect to earlier years.

(b) During the previous year ended 31 March 2026, the management reassessed whether the Company's Subsidiary, HCG Oncology LLP would have sufficient taxable profits to utilize its unused tax losses in the foreseeable future considering the improvement in its performance and utilization of tax losses accumulated in the earlier years. Accordingly, based on the reasonable certainty of availability of future profits in the foreseeable future, the Group recognized a deferred tax asset/credit of Rs. 960 lakhs on the brought forward business losses and unabsorbed depreciation with respect to this subsidiary.

7 During the previous year ended 31 March 2026, the Board of Directors had approved the introduction and adoption of the HCG Employee Stock Option Scheme 2026 ("HCG ESOS 2026"), under which the maximum number of options that can be granted is 74,21,455. Subsequent to the current quarter, the shareholders of the Company have, by way of special resolutions passed through postal ballot on 8 July 2026, approved (i) the introduction and adoption of HCG ESOS 2026 to eligible employees and (ii) the grant of up to 18,55,364 options (representing 1.24% of the diluted equity share capital) to Dr. Manish Mattoo, Executive Director and Chief Executive Officer of the Company, in one or more tranches. The implementation of HCG ESOS 2026 remains subject to receipt of approvals as may be required under applicable laws.

8 The Group has a single operating segment viz.of 'setting up and managing hospitals and medical diagnostic services'

For and on behalf of the Board of Directors

Dr. Manish Mattoo

Bangalore, 06 August 2026 **Executive Director And Chief Executive Officer**

HEALTHCARE GLOBAL ENTERPRISES LTD. Bengaluru

HEALTHCARE GLOBAL ENTERPRISES LIMITED
Regd Off: HCG Towers, # 8, P Kalinga Rao Road, Sampangi Ram Nagar, Bangalore – 560027
CIN: L15200KA1998PLC023489
Phone: +91 – 80 – 4660 7700, **Fax:** +91 – 80 – 4660 7749
Email: investors@hcgoncology.com; **Website:** www.hcgoncology.com

adding life to years

The Specialist in Cancer Care

EXTRACT OF THE CONSOLIDATED & STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

Particulars	Consolidated (Amount in Rs. Lakhs)				Standalone (Amount in Rs. Lakhs)			
	Quarter ended 30 June 2026	Preceding quarter ended 31 March 2026	Corresponding quarter ended 30 June 2025	Previous year ended 31 March 2026	Quarter ended 30 June 2026	Preceding quarter ended 31 March 2026	Corresponding quarter ended 30 June 2025	Previous year ended 31 March 2026
	Unaudited	(Refer note 2)	Unaudited	Audited	Unaudited	(Refer note 2)	Unaudited	Audited
Total income	70,723	66,540	61,999	257,040	38,622	36,513	33,503	139,497
Net profit for the period (before tax and exceptional items)	2,503	3,316	1,192	7,150	748	3,857	524	6,500
Exceptional items, net gain / (loss)	-	(3,191)	-	(4,458)	-	(4,752)	-	(5,538)
Net profit for the period (after tax and exceptional items)	1,646	404	598	2,278	558	153	345	1,458
Net profit for the period attributable to equity share holders of the company	1,377	217	475	1,376	558	153	345	1,458
Total comprehensive income for the period (Comprising net profit and other comprehensive income after tax) attributable to equity share holders of the company	1,424	426	492	1,831	558	142	345	1,466
Equity share capital	14,930	14,930	13,942	14,930	14,930	14,930	13,942	14,930
Earnings per share (of Rs.10 each) in Rs. Basic:	0.92	0.15	0.34	0.97	0.37	0.11	0.25	1.03
Earnings per share (of Rs.10 each) in Rs. Diluted:	0.92	0.15	0.33	0.96	0.37	0.11	0.24	1.03

Notes:

1. The above results were reviewed by the audit committee and approved by the board of directors at their meeting held on 06 August 2026

2. The figures for preceding quarter ended 31 March 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the end of the third quarter of the previous financial year, which were subject to limited review by the statutory auditors of the Company

3. The above is an extract from the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the NSE Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and at the Company's website (www.hcgoncology.com)

For HealthCare Global Enterprises Limited

Manish

Executive Director And Chief Executive Officer

Bangalore, 06 August 2026

HEALTHCARE GLOBAL ENTERPRISES LTD. ★ Bengaluru

AK